INTRODUCTION AND OBJECTIVES: Active surveillance (AS) of localized prostate cancer (PCa) in the UK involved protocol-driven (P) transrectal repeat biopsies (RB) plus serial digital rectal examination & PSA-testing, until NICE 2014 guidelines recommended multi-parametric magnetic resonance imaging (mpMRI) should drive RB where needed or replace P-RB. Interrogating our AS follow-up (F/U) data, we hypothesized that mpMRI reduces the number of RB required to drive therapeutic intervention (TI).
INTRODUCTION AND OBJECTIVES: Active surveillance (AS) has gained increased popularity for its role in reducing overtreatment of low-risk prostate cancer. One major concern about AS is the potential for understaging more aggressive disease. Additionally, men on AS are often subject to numerous prostate biopsies which also carries morbidity risk. Multiparametric MRI (mpMRI) of the prostate has demonstrated its ability to better detect clinically significant prostate cancer (CSPC) versus standard TRUS-biopsy alone. Using mpMRI, we aim to determine which men on AS are at risk of being upstaged, and which men could potentially avoid repeat biopsy while safely remaining on AS.
METHODS: We reviewed men on AS who underwent mpMRI of the prostate followed by MRI-TRUS (Uronav) fusion biopsy between January 2014 and May 2016. All men had a standard 12-core biopsy simultaneously or within the past 12 months. For this study, CSPC is defined as Gleason score !7. Using univariate and multivariate logistic regression analyses, we examined the effect of age, race, PSA, PSA density (PSAD), prostate volume by MRI, PIRADS score, lesion size, number of lesions, and DRE to determine the likelihood of upstaging to CSPC. The multivariate model was selected using Akaike Information Criterion to optimize model parsimony and fit.
RESULTS: A total of 101 men on AS underwent MRI-TRUS fusion biopsy. Patients had a median age of 66.5 years, PSA of 6.5ng/ mL, prostate volume of 47.9mL, and PSAD of 0.14. Univariate analysis revealed that PSA, PSAD, increasing PIRADS score, lesion size >2cm, and 3 or more lesions on MRI increased the odds of CSPC. Multivariate logistic regression demonstrated that PSAD !0.15 (OR 2.66, CI 1.0-7.03, p¼0.049) and increasing PIRADS score (PIRADS 4: OR 10.6, CI 2.1-53, p¼0.004; PIRADS 5: OR 15, CI 2.8-80, p¼0.002) were independent predictors of CSPC. Men with a PIRADS score of !3 with a PSAD !0.15 had a 55% chance of being upstaged to CSPC. Conversely, in men with PIRADS score 3 with a PSAD <0.15, no upstaging was seen ( Figure) .
CONCLUSIONS: In men on AS, the combination of mpMRI PSAD and PIRADS score predicts upstaging when PIRADS score is !3 with a PSA density !0.15. When this criteria is not met, men may potentially forgo repeat biopsy while safely maintaining them on AS. Further prospective study is warranted. RESULTS: There were 1413 patients identified, of which 353 met criteria for FIR. The mean age of the entire cohort was 60.8 AE 6.7 years. with median follow-up time of 30.0 (IQR 11.7-42.2) months. Rates of AP increased accordingly with risk group (Table 1) . The FIR group showed rates of AP between LR and UIR. On age-adjusted logistic regression analysis, risk grouping significantly correlated with AP (p<0.05). The cumulative survival-free BCR probabilities are also listed in Table 1 , with the FIR group demonstrating rates more similar to VLR/ LR than UIR. A Cox regression analysis controlling for age, ethnicity and prior biopsy status demonstrated similar hazard ratios (HR) for developing BCR in the LR (OR 6.1, 9% CI 1.3,28.8) and FIR (OR 5.88, 95% CI 1.3,25.8) groups, as opposed to higher HR in UIR ( OR 14.3, 95% CI 3.5, 59.1) , when compared to the reference group (VLR).
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CONCLUSIONS: Patients with FIR CaP have proportional rates of adverse pathology compared with lower risk CaP. However, intermediate-term clinical outcomes suggest more favorable clinical behavior, which may be related to the biology of these tumors. This has significant implications when considering patients for AS.
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OLDER AGE AT DIAGNOSIS AND DISEASE VOLUME PREDICT UPGRADING ON CONFIRMATORY BIOPSY IN PROSTATE CANCER PATIENTS BEING CONSIDERED FOR ACTIVE SURVEILLANCE INTRODUCTION AND OBJECTIVES: Prior single-institution retrospective studies suggest that age may independently predict risk of Gleason progression on repeat biopsy following a diagnosis of low risk prostate cancer (PCa). Older men experience higher rates of PCaspecific mortality; therefore, the appropriateness of active surveillance may differ in an older patient population and is influenced by the probability of undersampling for occult higher grade disease. Furthermore, the clinicopathologic features most useful in guiding decisions to re-biopsy remain poorly defined. We therefore sought to investigate the risk of Gleason upgrading on repeat biopsy, as well as the features most suggestive of potential Gleason misclassification.
METHODS: We retrospectively reviewed charts of 635 men on active surveillance at our institution between 2002 to 2015. Demographic and clinicopathologic features including age, race, initial PSA, prostate volume, clinical staging, and biopsy findings were collected. Within this population, we identified 556 men who were diagnosed with Gleason 3+3 disease on initial biopsy, of whom 406 received a documented confirmatory biopsy within 1 year of diagnosis. Logistic regression modeling was performed to determine features associated with detection of Gleason 7 or higher disease on confirmatory biopsy.
RESULTS: Eighty-five of 406 patients (21%) with initial Gleason 6 disease who received a repeat confirmatory biopsy were found to have grade reclassification. On multivariable analysis, older age (per year OR 1.07; 95% CI 1.02-1.11; p ¼ 0.003) and number of positive cores (per core, OR 1.38, 95% CI 1.10-1.73; p ¼ 0.05) were significantly associated with reclassification on confirmatory biopsy (Table 1) . Initial prostate volume, clinical stage, and PSA were not found to be associated with this risk.
